The most important trend in healthcare technology this year is not a model release. It is a spreadsheet exercise happening in the office of every health system CIO in the country: counting the vendors, and cutting the list.
Large systems commonly carry hundreds of distinct software vendors, accumulated through a decade of departmental purchases, innovation pilots, mergers and one-off point solutions. Each one carries a contract, a security review, an integration, a renewal cycle and a support relationship. The management overhead has outgrown the value, and boards have noticed.
Why the cut is happening now
Four pressures converged.
Margin compression made every recurring contract a target, and software is one of the few lines that can be cut without touching clinical staffing.
The security surface became a board-level risk. After a run of high-impact healthcare breaches and outages, every additional vendor with data access is a quantified liability, not just an operational cost. The number of third parties with protected health information is now something audit committees ask about by name.
The EHR vendors moved. Both major platforms have shipped or announced native capability in ambient documentation, messaging drafts, coding support and predictive analytics. When the incumbent ships an adequate version of your product inside the workflow the customer already owns, your differentiation has to be substantial rather than incremental, because "good enough and already integrated" wins procurement almost every time.
And integration capacity is the binding constraint. Even a system that wants your product may have a two-year queue for interface work. Vendor rationalisation is partly an attempt to free that team.
What this does to the market
Point solutions get squeezed from both sides. Above, by platforms bundling. Below, by the EHR. The middle is a hard place to be with a single workflow and a modest annual contract value. This is the mechanical explanation for why merger and acquisition activity in digital health has outpaced initial public offerings and why so many exits are landing at valuations well below the last private round. Consolidation on the buy side forces consolidation on the sell side.
Platform claims get audited. Every company now describes itself as a platform. Buyers have learned to test it: how many distinct workflows does one contract cover, does adding the second module require a new integration and a new security review, is there one data model underneath or three acquired products behind a shared logo. Fail that test and you are priced as a point solution regardless of your positioning.
Being acquired becomes a legitimate strategy rather than a failure. A company with strong clinical evidence, a differentiated data asset and a defensible workflow, but a modest total addressable market on its own, is worth more inside a platform. Founders who plan for that early, keeping architecture clean and data rights unencumbered, exit well. Founders who discover it during a down round do not.
What to do if you are building
Three moves, in rough order of leverage.
Widen the contract before you widen the product. The single best defence against rationalisation is being one of the vendors that survives it, which means covering more than one budget owner's problem. That can be achieved through partnership and interoperability as well as through building, and partnership is faster.
Make the security and integration story your sales advantage. If adopting you costs the customer's integration team two weeks instead of two quarters, say so with specifics, and make it verifiable. In a capacity-constrained environment, low implementation burden is a feature with real economic value.
Instrument your own displacement argument. Know which of the customer's existing contracts you can replace, name them in the proposal, and price against that saving. Rationalisation is a threat if you are being cut and a growth channel if you are the one doing the cutting.
The read for investors
The buy side is consolidating faster than the sell side, and that gap is where valuation compression lives. It also means the surviving winners will be larger and more durable than the last cycle produced, because they will be sitting on multi-workflow enterprise contracts rather than a portfolio of departmental pilots.
Fewer vendors does not mean less technology in healthcare. It means the technology arrives through fewer doors. Everything about a go-to-market plan should follow from that sentence.
